Accessibility Menu
ProPhase Labs logo

ProPhase Labs(NASDAQ) PRPH

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-98%
5 YearN/A
1 YearN/A
1 Month-47%
N/A
ProPhase Labs last closing stock price
MetricPriceDate
Last closeUSD 0.042026-08-03
ProPhase Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-32.6%USD 0.062026-07-27
1 month-46.86%USD 0.082026-07-02
3 month-72.09%USD 0.152026-05-05
Since inception-98.44%USD 2.661992-11-09

ProPhase Labs Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.39M

Net Income (TTM)

-$24.06M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 12, 2026

PRPH News

Foolcom-Featured.png

ProPhase Labs Posts Narrower Q2 Loss

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ProPhase Labs

ProPhase Labs makes over-the-counter supplements and health tests for everyday consumers. Its products help with energy, wellness, and personal health tracking. The company also develops new drug candidates and genomics services for broader health needs.

What’s in the ProPhase Medicine Cabinet?

  • Dietary Supplements (100% revenue Q2 2025): Pills and capsules for energy, stamina, and male health, sold in U.S. stores and online.
  • Genomics Services: DNA testing and whole genome sequencing for consumers, helping people learn about their health risks.
  • Contract Manufacturing: Product development and packaging for other supplement brands, including warehousing and shipping.
  • Drug Development: Research and licensing of new drugs and supplements, including candidates for viral infections and cancer screening.
  • Diagnostic Testing (inactive in 2025): Previously offered COVID-19 and respiratory virus tests, now paused.

Growth Spurts and Strategic Moves

  • Sold Pharmaloz Manufacturing and Pharmaloz Real Estate Holdings in January 2025, reducing debt and costs.
  • Launched DNA Complete in September 2024 to expand genomics offerings.
  • Acquired BE-Smart esophageal pre-cancer test from Stella Diagnostics in 2023, with validation study completed June 2025.
  • Secured $3M in aggregate principal investment in new financing in July 2025 to support operations and product launches.
  • Expanded direct-to-consumer genomics through Nebula Genomics and new retail channels in 2024-2025.

Why ProPhase Stands Out in the Crowd

ProPhase combines supplements, genomics, and drug development under one roof. Its proprietary BE-Smart test and exclusive drug licenses set it apart. The company adapts quickly, shifting focus as market needs change.

Five Things You Need to Know

  • Revenue was $883,000 in Q3 2025, down 71.9% from Q3 2024.
  • Consumer Products made up 100% of revenue in Q2 2025.
  • Net loss was $-123,000 in Q3 2025, improved 25.5% year-over-year.
  • Cash and cash equivalents were $169,000 as of June 30, 2025.
  • Gross margin for Consumer Products rose to 67.8% in Q2 2025.

Bottom Line

ProPhase has shifted from diagnostics to supplements and genomics, focusing on new product launches. The company faces financial challenges but continues to diversify its health offerings.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19

CEO

Ted William Karkus, MBA

Website

www.prophaselabs.com

Headquarters

Uniondale, NY 11556, US

PRPH Financials

Key Financial Metrics (TTM)

Gross Margin

30.22%

Operating Margin

-500.85%

Net Income Margin

-709.40%

Return on Equity

-453.74%

Return on Capital

-148.83%

Return on Assets

-40.96%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$1.03M

Operating Income

-$16.99M

EBITDA

-$9.03M

Operating Cash Flow

-$30.85M

Capital Expenditure

$0.00

Free Cash Flow

-$30.85M

Cash & ST Invst.

$31.00K

Total Debt

$8.91M

ProPhase Labs Performance Analysis

ProPhase Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 122,647,00055.2%
20232023-12-31USD 34,984,000-71.5%
20242024-12-31USD 6,770,000-80.6%
20252025-12-31USD 4,345,000-35.8%
ProPhase Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-12.9%
Q32025-09-30-29.2%
Q42025-12-31-11.2%
Q12026-03-31-39.0%
ProPhase Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 10.24158.9%
20232023-12-31USD -9.75N/A
20242024-12-31USD -26.08167.4%
20252025-12-31USD -2.77-89.4%
ProPhase Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-152.4%
Q32025-09-30-45.5%
Q42025-12-3145.6%
Q12026-03-3150.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$478.00K

-66.6%

Gross Profit

$167.00K

-68.3%

Gross Margin

34.94%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

19

N/A

Net Income

-$5.35M

-235.0%

EBITDA

-$2.37M

+6.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$31.00K

-64.8%

Total Debt

$8.91M

-36.4%

Accounts Receivable

$1.54M

-92.4%

Inventory

$70.00K

-93.9%

Long Term Debt

$448.00K

-94.5%

Short Term Debt

$8.46M

+45.8%

Return on Assets

-40.96%

N/A

Return on Invested Capital

-5.42%

N/A

Free Cash Flow

-$748.00K

+77.9%

Operating Cash Flow

-$748.00K

+77.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AYTUAytu BioPharma, Inc.
$2.27+0.89%
TXMDTherapeuticsMD, Inc.
$2.05+0.49%
ERNAErnexa Therapeutics Inc.
$4.11+18.99%
BFRIBiofrontera Inc.
$1.23+3.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$160.70+0.28%
AMIXAutonomix Medical
$10.97+2.01%
NOKNokia
$10.00+0.07%
INTCIntel
$100.22+0.10%

Questions About PRPH

What is the current price of ProPhase Labs?

ProPhase Labs is trading at N/A per share.

What is the 52-week range for ProPhase Labs?

Over the past 52 weeks, ProPhase Labs has traded between N/A and N/A.

How much debt does ProPhase Labs have?

As of the most recent reporting period, ProPhase Labs reported total debt of $8.91M.

How much cash does ProPhase Labs have on hand?

ProPhase Labs reported $31.00K in cash and cash equivalents in its most recent financial results.

What is ProPhase Labs’s dividend yield?

ProPhase Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services